GoTo Foods Embraces 'Ozempic Era': Smaller Portions and Protein-Forward Menus
GoTo Foods is reimagining its menu as GLP-1 medications reshape consumer preferences. By focusing on smaller portions and protein-first offerings, brands like Cinnabon and Jamba are adapting to the 'Ozempic era.'
In the wake of rising GLP-1 medication use, GoTo Foods is strategically reshaping its offerings. With brands like Cinnabon and Jamba under its wing, the company is pivoting to embrace the 'Ozempic era,' characterized by a focus on smaller, protein-forward menu items.
Chronology
The story begins as GLP-1 drugs, known for their appetite-suppressing effects, gain traction in the consumer market. GoTo Foods CEO Omer Gajial has recognized the implications of these medications, which are expected to see significant uptick in use over the coming years. Rather than ignoring this trend, the company is proactively adjusting its menu to meet evolving consumer needs.
Over the past few months, GoTo Foods has been refining its strategy. At Moe's Southwest Grill, for instance, they simply repositioned existing offerings, highlighting the protein content in bowls, 68 grams, to be precise. Gajial's approach is more about emphasizing what's already there than reinventing the wheel.
Impact
This shift isn't just about marketing. There's a tangible financial rationale. As consumers increasingly opt for smaller portions, often through the kids' menu to avoid excessive quantities, GoTo Foods is navigating the fine line between satisfying this demand and maintaining margins. Nearly 25% of GLP-1 users choose kid-sized meals, affecting the bottom line for traditional serving sizes.
Cinnabon and Jamba aren't immune to these changes. The 'small indulgences' model is becoming important. Smaller portions don't just reduce calories, they align with broader dietary trends among fitness enthusiasts and macro-focused consumers, proving this is more than a niche concern. It's mainstream.
Yet, the GLP-1 branding paradox remains a challenge. Research indicates over a third of consumers reject overtly labeled 'GLP-1-friendly' products. Making this transition smoothly without alienating customers is key.
Outlook
So, where does this pivot leave GoTo Foods? The company is unveil new menu strategies in the coming months, hinting at increased 'stretchability', brands like Jamba can function as both snack hubs and full-fledged dining spots. This adaptability could prove advantageous.
As appetite economics evolve, GoTo Foods is crafting its menu to offer customers genuine choice. Smaller formats, protein highlights, all without the stigma of GLP-1 labels. The challenge will be executing these changes without complicated workflows or delivery issues.
Ultimately, the question isn't whether GoTo Foods will succeed in the Ozempic era, but how quickly others will adapt. Who will be left behind in this culinary transition? The intersection is real. Most won't make it, but the players who do will reshape the industry. That's the gamble.
